Since siltuximab neutralizes IL-6, it has been approved by FDA for phase III clinical trials for hospitalized patients suffering from COVID-19-related acute respiratory distress syndrome (ARDS) [180]. This evidence concerns the gene IL6 and acute respiratory distress syndrome.